Cite

Haemoglobin (Hb) values in subgroups of patients

Hb (g/L)No. of patientsMedian Hb (g/L)Hb range (g/L)
Pre-treatment Hb12886–169
  > 120 g/L69136122–169
  ≤ 120 g/L3110786–120
Mean on-treatment Hb12796–157
  >120 g/L67134121–157
  ≤ 120 g/L3311396–119
End-of-treatment Hb12177–159
  > 120 g/L46134121–159
  ≤ 120 g/L5411477–120

Acute treatment toxicities

ToxicityGrade
01234Total
Stomatitis68121091100
Nausea, vomiting799930100
Diarrhoea571712131100
Hand-foot syndrome

Only in patients treated with capecitabine

22012025
Radiodermatitis101213641100
Infection51142393100
Leucocyte count373120102100
Haemoglobin level43441120100
Platelet count5836330100

Univariate analysis of survival of patients at 5 years by Hb level, tumour-, patients-, and treatment characteristics

CharacteristicsnLRCDFSDSSOS
Pre-treatment Hb
79%77%85%73%
 > 120 g/L69
57%57%56%39%
 ≤ 120 g/L31
P = 0.011P = 0.017P = 0.003P = 0.000
Mean on-treatment Hb
78%76%82%68%
 > 120 g/L67
60%60%67%50%
 ≤ 120 g/L33
P = 0.037P = 0.054P = 0.081P = 0.007
End-of-treatment Hb
82%80%89%75%
 > 120 g/L46
63%63%65%49%
 ≤ 120 g/L54
P = 0.022P = 0.037P = 0.011P = 0.003
Performance status
73%73%80%72%
  PS 076
69%64%66%34%
  PS 1–324
P = 0.480P = 0.283P = 0.231P = 0.000
Tumour stage
75%75%84%68%
T1–386
50%44%38%25%
T414
P = 0.054P = 0.015P = 0.000P = 0.001
Lymph node involvement
no6579%79%87%70%
yes3559%56%60%48%
P = 0.032P = 0.017P = 0.000P = 0.000
Overall disease stage
79%79%87%70%
I / II
64
IIIA / IIIB59%57%61%49%
36
P = 0.044P = 0.025P = 0.000P = 0.000
Histologic tumour type
basaloid12100%100%100%100%
squamous8868%67%74%57%
P = 0.030P = 0.026P = 0.051P = 0.016
Tumour site
69%68%78%62%
anal canal72
81%81%73%61%
anal margin28
P = 0.250P = 0.212P = 0.994P = 0.738
Blood transfusion
no72%71%78%64%
91
yes0%0%0%0%
9
P = 0.993P = 0.950P = 0.333P = 0.044
Overall radiation time
89%89%93%83%
≤ 1,08 months29
64%63%69%51%
> 1,08 months71
P = 0.015P = 0.011P = 0.012P = 0.012
Operation
no7389%88%88%69%
yes2729%29%52%45%
P = 0.000P < 0.000P = 0.001P = 0.018

Patients’ and tumours’ characteristics

CharacteristicsNo. of patients
Gender
 female60
 male40
Mean age (range)63 (34–87)
Performance status (WHO)
 076
 120
 23
 31
Tumour type
 Carcinoma of the anal canal72
 Carcinoma of the anal margin28
Tumour histology
Basaloid12
Squamous88
TNMN0N1N2N3
 T19010
 T236610
 T3191031
 T41175
Tumour stage
 I9
 II55
 IIIA17
 IIIB19
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Radiology, Internal Medicine, Haematology, Oncology